{"id":"NCT02006654","sponsor":"H. Lundbeck A/S","briefTitle":"Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor","officialTitle":"Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2017-01","completion":"2017-01","firstPosted":"2013-12-10","resultsPosted":"2018-02-07","lastUpdate":"2018-02-07"},"enrollment":734,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Idalopirdine","otherNames":["Lu AE58054"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Idalopirdine 60 mg (or 30 mg)","type":"EXPERIMENTAL"}],"summary":"To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).","primaryOutcome":{"measure":"Change in Cognition","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.68,"sd":0.37},{"arm":"Idalopirdine 60 mg (or 30 mg)","deltaMin":0.13,"sd":0.38}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2365"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":107,"countries":["United States","Australia","Brazil","Czechia","Germany","Israel","Mexico","Serbia","Singapore","Slovakia","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["31193334","30474567","29318278"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":365},"commonTop":["Accidental overdose","Fall","Gamma-glutamyltransferase increased","Aspartate aminotransferase increased"]}}